Atropine and Spectacle Combination Treatment (ASPECT): 12-month Results of a Randomized Clinical Trial for Myopia Control

Launched by HOSPITAL SAN CARLOS, MADRID · May 21, 2024

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • Age between 4-16 years.
• • Signing of informed consent.
• • Refractive error: myopia greater than -1.00 diopters (D).
• • Myopia progression of at least -0.50 D in the last 12 months.
• • Astigmatism of 2 D or less and anisometropia of 1.50 D or less.
• • Best-corrected monocular visual acuity (VA) of 0.2 logMAR(6/9) or better.
• • Exclusion criteria
• • Children under 4 years old and over 16 years old
• • Strabismus and binocular vision anomalies.
• • Alterations in eye fundus that the researcher consider necessary the patient exclution.
• • Ocular pathology of the anterior segment (media opacity such as cataracts, glaucoma, aphakia, pseudophakia, uveitis, keratoconus or surface alterations), and any pathology of the posterior segment that prevents correct vision
• • Amblyopia
• • Previous eye surgery
• • Systemic pathology (cardiopulmonary pathology, connective tissue alterations, neurological or psychiatric pathology) or baseline situation of the patient that does not allow the examination to be carried out (such as mental or psychomotor retardation)
• • Previous myopia control treatments including orthokeratology, rigid contact lenses, bifocal or myopia control soft contact lenses, bifocal and multifocal ophthalmic lenses within 3 months prior to the study.